High Content Screening Drug Discovery

Hcs integrates high throughput methodologies with automated multicolor fluorescence microscopy to collect quantitative morphological and molecular data from complex biological systems.

High content screening drug discovery. Discovery of a novel rock2 inhibitor with anti migration effects via docking and high content drug screening 1 january 2016 molecular biosystems vol. Paper phenotypic drug discovery with high content screening target based or phenotypic screening. 9 high content screening identifies inhibitors of the nuclear translocation of atf6. High content screening hcs also known as high content analysis hca or cellomics is a method that is used in biological research and drug discovery to identify substances such as small molecules peptides or rnai that alter the phenotype of a cell in a desired manner.

A decade ago there was talk that high throughput screening hts was a contributory factor in drug discovery s declining productivity and that it stifled creativity and innovation. Read more optimising phenotypic screening single cell analysis versus 3d multicell analysis by dr richard m. Recent developments in high content screening hcs technologies make it an attractive alternative for anti angiogenic drug discovery. It can be employed in drug discovery projects to optimize compound series on their safety profile and provide a risk assessment tool towards candidate selection.

These types of assays are often referred to as high content screening or high content analysis hcs hca. In this study we present a novel high content screening assay which is highly predictive for human drug induced liver injury dili. 1 but the last ten years have certainly disproved those claims with hts playing a role in the discovery of many new drugs and moving from the preserve of large pharma to a method available to smaller companies. High content screening hcs has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of covid 19 and beyond.

The driving force to adopt imaging for drug development is the quantity and quality of cellular information that can be collected and the enhanced physiological relevance of cellular screening compared to biochemical screening. This demand resulted in the use of cell based screening as a method of choice in drug discovery 1 2 high content screening hcs is multiplexed functional cell based screening 3 4 5 6 hcs can be used in all aspects of drug discovery as an engine for driving.